Could a low-dose immune therapy improve autism symptoms?
NCT ID NCT07589842
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests whether low doses of interleukin-2 (ILT-101) can help children aged 6 to 8 with autism spectrum disorder whose mothers had an immune condition during pregnancy. The treatment aims to boost certain immune cells (Tregs) that may be out of balance. The trial involves 22 participants and will measure changes in immune markers and behavior over several months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Robert Debré Hospital
Paris, 75019, France
Conditions
Explore the condition pages connected to this study.